In vitro anticancer activity of chloro(N-phenyl-N'-[(pyridin-2- yl)methylidene]carbamohydrazonothioato) (4-aminobenzene-1-sulfonamide)copper [Articol]

Abstract

This study was aimed to evaluate the antiproliferative activity of the mixed-ligand complex (chloro(N-phenyl-N'-[(pyridin-2-yl)methylidene]carbamohydrazonothioato)(4-aminobenzene-1-sulfonamide)copper) on several cancer cells of lines. It was established, that the copper(II) mixed-ligand complex exhibits the highest anticancer activity against MeW-164, HeLa, BxPC-3 and RD cells of lines with IC50 values of 1.0±0.2, 0.4±0.04, 1.7±0.2, 1.3±0.3 µM, respectively. A comparative study between the tested compound and DOXO in regard to cancer lines has established that the tested copper(II) mixed-ligand complex exhibits stronger inhibitory activity on cancer cells proliferation than doxorubicin and cisplatin.

Acest studiu a avut ca scop studierea activității antiproliferative a complexului (cloro(N-fenil-N'-[(piridin-2-il)metiliden]carbamohidrazontiolato)(4-aminobenzen-1-sulfonamid)-cupru) pe linii de celule cancerigene. S-a stabilit că complexul investigat cu cupru (II) prezintă cea mai mare activitate anticancerigenă împotriva celulelor liniilor MeW-164, HeLa, BxPC-3 și RD cu valori IC50 de 1,0±0,2, 0,4±0,04, 1,7±0,2, 1,3±0,3, respectiv. Studiul comparativ al compusului testat cu DOXO în ceea ce privește liniile de celule cancerigene a arătat că complexul testat de cupru (II) prezintă o activitate inhibitoare mai puternică asupra proliferării celulelor cancerigene decât doxorubicina și cisplatina.